NCT00417677终止1 期
A Phase I/II Study of Temsirolimus and Sunitinib in Subjects With Advanced Renal Cell Carcinoma
Wyeth is now a wholly owned subsidiary of Pfizer4 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2007年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 124
- 试验地点
- 4
- 主要终点
- Initially, an ascending dose design will be used in order to evaluate the tolerability and safety of the combination and to determine the MTD of this combination (dose escalation phase)
研究概览
简要总结
This study is being conducted to determine the Maximum Tolerated Dose (MTD) and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
详细描述
A study to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of temsirolimus and sunitinib in subjects with advanced Renal Cell Carcinoma (RCC) (dose escalation phase). Once the MTD is determined, this study will also evaluate the efficacy of this combination by determining progression free survivial (PFS) at 12 months in subjects with advanced RCC (expanded cohort phase).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •for Dose Escalation Phase
- •Histologically confirmed advanced RCC.
- •Up to 2 prior systemic regimens for RCC.
- •Subject must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral computed CT (5-mm slice thickness contiguous) or ³20 mm when measured by conventional CT (10-mm slice thickness contiguous) (lesion must be ³ 2 times the size of the slice thickness per RECIST).
- •More criteria apply
排除标准
- •for Dose Escalation Phase
- •Subjects with known active central nervous system (CNS) malignancy (primary or metastatic).
- •Prior therapy with sirolimus, temsirolimus or sunitinib.
- •Subjects receiving known strong Cytochrome P450 (CYP)3A4 isoenzyme inhibitors and/or inducers. Subjects receiving other CYP3A4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
- •More criteria apply
- •Inclusion Criteria for Expanded Cohort Phase
- •Subjects with histologically confirmed advanced RCC regardless of nephrectomy status who have received no prior systemic therapies for their disease.
- •Subjects with histologically confirmed advanced RCC regardless of nephrectomy status who have a least 4 weeks since prior treatment with palliative radiation therapy, and/or surgery and resolution of all toxic effects of prior therapy to NCI CTCAE (version 3.0) grade £
- •Subjects must have at least 1 measurable lesion that can be accurately measured in at least 1 dimension with the longest diameter ³10 mm when measured by spiral CT (5-mm slice thickness contiguous) or ³20 mm when measured by conventional CT (10-mm slice thickness contiguous) (lesion must be ³2 times the size of the slice thickness per RECIST).
- •More Criteria apply
- •Exclusion Criteria for the Expanded Cohort Phase
- •Subjects with a history of a CNS malignancy or metastatic disease to the CNS and subjects with a known, active CNS malignancy (primary or metastatic).
- •Prior anti-vascular endothelial growth factor (anti-VEGF) therapies (with either monoclonal antibodies and/or tyrosine kinase inhibitors [TKIs]) and/or mTOR inhibitors.
- •Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers. Subjects taking other CYP3A4 isoenzyme inhibitors and/or inducers not classified as strong inhibitors or inducers are eligible, provided they have been on a stable regimen for at least 4 weeks before screening.
- •More Criteria apply
结局指标
主要结局
Initially, an ascending dose design will be used in order to evaluate the tolerability and safety of the combination and to determine the MTD of this combination (dose escalation phase)
Once appropriate doses of each agent have been determined, an expanded cohort of 100 subjects with advanced RCC will be enrolled and treated at the MTD, to obtain further safety and efficacy information
次要结局
- To examine additional efficacy endpoints including: Response rate (RR), Overall Survival (OS), & Progression Free Survival at 6 months and 24 months.
- To determine the pharmacokinetic (PK) parameters of temsirolimus alone and temsirolimus and sunitinib in combination
- PK samples will be collected from 20 subjects in the expanded cohort. Concentrations of temsirolimus, sirolimus, and sunitinib will be analyzed using a noncompartmental modeling approach.The PK parameters will include estimation of the peak concentr
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)Renal Cell CancerKidney CancerNCT01122615M.D. Anderson Cancer Center23
Unknown
2 期
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With GlioblastomaGlioblastoma MultiformeNCT02928575Bassam Abdulkarim45
已完成
1 期
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00255658National Cancer Institute (NCI)40
已完成
1 期
Study of Axitinib and Temsirolimus in Solid TumorsCancerNCT01529138Emory University13
已完成
1 期
Temsirolimus and Sorafenib in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT01008917University of California, San Francisco25